Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the production of tetrahydrofolate needed for DNA and RNA synthesis. This limits the replication of rapidly dividing cells and dampens immune‑mediated inflammation, providing therapeutic effects in both autoimmune and malignant conditions.

The specific dose of Metex is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and other individual factors. Dosage regimens are individualized and should follow the prescriber’s written instructions.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in breast milk and affect the infant.

To request Metex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with biologic agents such as TNF‑α inhibitors, methotrexate is a small‑molecule antimetabolite that is less expensive and can be administered subcutaneously. While biologics target specific cytokines, methotrexate has a broader mechanism affecting DNA synthesis, which may be advantageous in certain cancers but requires more laboratory monitoring.

Metex should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Proper cold‑chain storage helps maintain drug stability and potency.

Metex is supplied for subcutaneous injection. The injection is typically given by a healthcare professional or trained patient using a sterile needle and syringe. The injection site is rotated to minimize local irritation, and proper aseptic technique must be followed.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, and renal failure. Patients should be monitored regularly for liver enzymes, lung function, blood counts and kidney parameters to detect early signs of toxicity.

Metex is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver disease, uncontrolled infections, and those with significant renal impairment. It should also be used with caution in the elderly and in patients receiving other immunosuppressive therapies.